MARKETS / COMPANIES / ECONOMYRSS edition ↗
Dividend Outlook
Market News

Schott Poonawalla now becomes Schott Pharma, as it strengthens presence

SENSEX 73,246.03 -352.64 NIFTY 22,698.85 -50.90 CRUDEOIL 9,757.00 + 259.00 GOLD 143,785.00 -353.00 SILVER 194,650.00 -2,067.00 SENSEX 73,246.03 -352.64 NIFTY 22,698.85 -50.90 NIFTY 22,698.85 -50.90 CRUDEOIL 9,757.00 +…

Schott Poonawalla now becomes Schott Pharma, as it strengthens presence
SENSEX 73,246.03

 -352.64

NIFTY 22,698.85

 -50.90

CRUDEOIL 9,757.00

+ 259.00

GOLD 143,785.00

 -353.00

SILVER 194,650.00

 -2,067.00

SENSEX 73,246.03

 -352.64

NIFTY 22,698.85

 -50.90

NIFTY 22,698.85

 -50.90

CRUDEOIL 9,757.00

+ 259.00

CRUDEOIL 9,757.00

+ 259.00

GOLD 143,785.00

 -353.00

'; } document.getElementById("lgdv").innerHTML = htmlElements; } function numberformat(i) { return Number(parseFloat(i).toFixed(2)).toLocaleString('en', { minimumFractionDigits: 2 }) } async function gatherResponse(response) { const { headers } = response; const contentType = headers.get('content-type') || ''; if (contentType.includes('application/json')) { return await response.json() } return response.text(); } function getWidth() { if (Math.max(document.body.scrollWidth,document.documentElement.scrollWidth,document.body.offsetWidth,document.documentElement.offsetWidth,document.documentElement.clientWidth) > 991) { document.getElementById("mob").style.display = "none"; document.getElementById("lgdv").style.display = "block"; } else { document.getElementById("mob").style.display = "block"; document.getElementById("lgdv").style.display = "none"; } } getWidth(); THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.

Roy Joseph, CEO & Managing Director, Schott Pharma India Private Ltd, said, the company remained focussed on growing and contributing to the safe and reliable delivery of critical therapies to patients worldwide

By BL Mumbai Bureau

Updated - October 28, 2026 at 09:18 PM.

Specialty glass company Schott Poonawalla Private Ltd will become Schott Pharma India Private Ltd, from Wednesday - strengthening its connection with German parent Schott Pharma, besides marking a new journey in the domestic market, it said.

The new identity brings together the company’s strong manufacturing footprint, long-standing customer relationships and deep market expertise in India with Schott Pharma’s global capabilities, innovation and scientific excellence, it said, adding that there was no change in ownership, management, employees, business strategy, operations, products, services or existing customer commitments.

The development comes at a time when media reports indicate that the company is taking steps to go in for an initial public offering. Last year, private equity firm TPG had acquired 35 per cent stake in Schott Poonawalla from Serum Institute of India (SII), following which Adar Poonawalla’s SII held a minority stake in the company.

Responding to a businessline query on the shareholding pattern and the possible IPO, the company said, ‘the shareholding structure remains same, as it has always been. There is no change to the legal structure or operations of the organization except for the name being changed to Schott Pharma India’

Pharma hub

“Schott Pharma India plays a critical role in patient care. With more than 3 billion containers produced annually, this company enables around 7,000 injections to reach patients every minute,” said Dr Christian Mias, CEO of Schott Pharma AG & Co, the India arm’s major shareholder.

“The name change .... reinforces our strategic partnership and confirms our long-term commitment to India as a key pharma hub,” Mias added.

Roy Joseph, CEO & Managing Director, Schott Pharma India Private Ltd, said, the company remained focussed on growing and contributing to the safe and reliable delivery of critical therapies to patients worldwide.

The company said, during COVID-19, its pharmaceutical vials supported more than 4.3 billion vaccine doses worldwide, including 3 billion doses in India.

“As India’s only manufacturer of glass pre-fillable syringes and sterile formats, the company also strengthens local supply capabilities. Furthermore, the company continues to invest significantly towards manufacturing capacity expansions of pre-fillable syringes and cartridges, strengthening their ability to support the rapidly evolving needs of biologics, biosimilars, GLP-1 based treatments and other advanced injectable therapies,” it said.

Published on October 28, 2026

THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.Sign into Unlock benefits!
  • Access 10 free stories per month
  • Get notified by email for early preview to new features, discounts & offers
Source: The Hindu BusinessLine — Companies ↗

Figures reflect the source report and its stated period. This article is for information and is not investment advice.